Integra Lifesciences Holdings (FRA:IL3) LT-Debt-to-Total-Asset : 0.04 (As of Mar. 2024)

View and export this data going back to . Start your Free Trial

What is Integra Lifesciences Holdings LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Integra Lifesciences Holdings's long-term debt to total assests ratio for the quarter that ended in Mar. 2024 was 0.04.

Integra Lifesciences Holdings's long-term debt to total assets ratio declined from Mar. 2023 (0.43) to Mar. 2024 (0.04). It may suggest that Integra Lifesciences Holdings is progressively becoming less dependent on debt to grow their business.

Integra Lifesciences Holdings LT-Debt-to-Total-Asset Historical Data

The historical data trend for Integra Lifesciences Holdings's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Integra Lifesciences Holdings LT-Debt-to-Total-Asset Chart

Integra Lifesciences Holdings Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.42

0.41

0.42

0.40

0.44

Integra Lifesciences Holdings Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.43	0.40	0.43	0.44	0.04

Integra Lifesciences Holdings LT-Debt-to-Total-Asset Calculation

Integra Lifesciences Holdings's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (A: Dec. 2023 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2023 )	/	Total Assets (A: Dec. 2023 )
	=	1514.762	/	3468.083
	=	0.44

Integra Lifesciences Holdings's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2024 is calculated as

LT Debt to Total Assets (Q: Mar. 2024 )	=	Long-Term Debt & Capital Lease Obligation (Q: Mar. 2024 )	/	Total Assets (Q: Mar. 2024 )
	=	156.475	/	3751.966
	=	0.04

Integra Lifesciences Holdings (FRA:IL3) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Integra Lifesciences Holdings LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Integra Lifesciences Holdings's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Integra Lifesciences Holdings (FRA:IL3) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Integra Lifesciences Holdings Corp (FRA:IL3) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

IART:USA

Address

1100 Campus Road, Princeton, NJ, USA, 08540

Website

https://www.integralife.com

Integra Lifesciences Holdings Corp is a New Jersey-based medical equipment company focused on developing products for regenerative therapy, extremity orthopedics, and neurosurgical applications. The firm is organized into two primary segments: Codman specialty surgical and tissue technologies. Codman specialty surgical generates maximum revenue from its segmental operations. Integra serves Europe, Asia Pacific, and the rest of the world whilst it derives key revenue from domestic sales.

Integra Lifesciences Holdings (FRA:IL3) Headlines

No Headlines